News Gilead, Arcus say TIGIT combo encouraging in GI cancer Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer immunotherapies have shuffled forwards again, with new data showing signs of efficacy
Events Partner Content FREE - Gastrointestinal Cancer Drug Development Digital Summ... FREE - Gastrointestinal Cancer Drug Development Summit
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
